48770 Federal Register / Vol. 82, No. 202 / Friday, October 20, 2017 / Rules and Regulations 

C. Paperwork Reduction Act (PRA) 

This action does not impose an 

information collection burden under the 

provisions of the Paperwork Reduction 

Act, 44 U.S.C. 3501 et seq. 

D. Regulatory Flexibility Act (RFA) 

I certify that this action will not have 

a significant economic impact on a 

substantial number of small entities 

under the RFA. This action will not 

impose any requirements on small 

entities. 

E. Unfunded Mandates Reform Act 

(UMRA) 

This action does not contain an 

unfunded mandate of $100 million or 

more as described in UMRA, 2 U.S.C. 

1531–1538, and does not significantly or 

uniquely affect small governments. 

F. Executive Order 13132: Federalism 

This action does not have federalism 

implications. It will not have substantial 

direct effects on the states, on the 

relationship between the national 

government and the states, or on the 

distribution of power and 

responsibilities among the various 

levels of government. 

G. Executive Order 13175: Consultation 

and Coordination With Indian Tribal 

Governments 

This action does not have tribal 

implications, as specified in Executive 

Order 13175. It will not have substantial 

direct effects on any Indian tribes, on 

the relationship between the federal 

government and Indian tribes, or on the 

distribution of power and 

responsibilities between the federal 

government and Indian tribes. Thus, 

Executive Order 13175 does not apply 

to this action. 

H. Executive Order 13045: Protection of 

Children From Environmental Health 

Risks and Safety Risks 

The EPA interprets Executive Order 

13045 as applying only to those 

regulatory actions that concern health or 

safety risks that the EPA has reason to 

believe may disproportionately affect 

children, per the definition of ‘‘covered 

regulatory action’’ in section 2–202 of 

the Executive Order. This action is not 

subject to Executive Order 13045 

because it merely rescinds a FIP 

covering a generating station that has 

been decommissioned and demolished. 

I. Executive Order 13211: Actions 

Concerning Regulations That 

Significantly Affect Energy Supply, 

Distribution, or Use 

This action is not subject to Executive 

Order 13211 because it is not a 

significant regulatory action under 

Executive Order 12866. 

J. National Technology Transfer and 

Advancement Act 

This rulemaking does not involve 

technical standards. The EPA is not 

revising any technical standards or 

imposing any new technical standards 

in this action. 

K. Executive Order 12898: Federal 

Actions To Address Environmental 

Justice in Minority Populations and 

Low-Income Populations 

The EPA believes that this action does 

not have disproportionately high and 

adverse human health or environmental 

effects on minority populations, lowincome populations, and/or indigenous 

peoples, as specified in Executive Order 

12898 (59 FR 7629, February 16, 1994). 

The documentation for this decision is 

contained in section III above. 

L. Determination Under Section 307(d) 

Pursuant to CAA section 307(d)(1)(B), 

the EPA has determined that this action 

is subject to the provisions of section 

307(d). Section 307(d) establishes 

procedural requirements specific to 

certain rulemaking actions under the 

CAA. Pursuant to CAA section 

307(d)(1)(B), the rescission of the MGS 

FIP is subject to the requirements of 

CAA section 307(d), as it constitutes a 

revision to a FIP under CAA section 

110(c). Furthermore, CAA section 

307(d)(1)(V) provides that the 

provisions of section 307(d) apply to 

‘‘such other actions as the Administrator 

may determine.’’ The EPA determines 

that the provisions of 307(d) apply to 

the EPA’s action on the MGS FIP 

rescission. 

M. Congressional Review Act (CRA) 

This rule is exempt from the CRA 

because it is a rule of particular 

applicability. The EPA is not required to 

submit a rule report regarding this 

action under section 801 because this is 

a rule of particular applicability that 

only applies to a single, 

decommissioned facility. 

N. Petitions for Judicial Review 

Under CAA section 307(b)(1), 

petitions for judicial review of this 

action must be filed in the United States 

Court of Appeals for the appropriate 

circuit by December 19, 2017. Filing a 

petition for reconsideration by the 

Administrator of this final rule does not 

affect the finality of this rule for the 

purposes of judicial review nor does it 

extend the time within which a petition 

for judicial review may be filed, and 

shall not postpone the effectiveness of 

such rule or action. 

List of Subjects in 40 CFR Part 52 

Environmental protection, Air 

pollution control, Incorporation by 

reference, Sulfur oxides. 

Authority: 42 U.S.C. 7401 et seq. 

Dated: October 13, 2017. 

E. Scott Pruitt, 

Administrator, EPA. 

For the reasons set forth in the 

preamble, EPA amends 40 CFR part 52 

as follows: 

PART 52—APPROVAL AND 

PROMULGATION OF 

IMPLEMENTATION PLANS 

■ 1. The authority citation for part 52 

continues to read as follows: 

Authority: 42 U.S.C. 7401, et seq. 

Subpart DD—Nevada 

§ 52.1488 [Amended] 

■ 2. Section 52.1488 is amended by 

removing and reserving paragraph (d). 

[FR Doc. 2017–22701 Filed 10–19–17; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

42 CFR Part 493 

[CMS–3271–F] 

RIN 0938–AS04 

Clinical Laboratory Improvement 

Amendments of 1988 (CLIA); Fecal 

Occult Blood (FOB) Testing 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS; Centers 

for Disease Control and Prevention 

(CDC), HHS. 

ACTION: Final rule. 

SUMMARY: This final rule amends the 

Clinical Laboratory Improvement 

Amendments of 1988 (CLIA) regulations 

to clarify that the waived test 

categorization applies only to nonautomated fecal occult blood tests. 

DATES: These regulations are effective 

December 19, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, CDC, (404) 498–2280, 

or Daralyn Hassan, CMS, (410) 786– 

9360. 

SUPPLEMENTARY INFORMATION: 


nlaroche on DSK9F9SC42PROD with RULES
Federal Register / Vol. 82, No. 202 / Friday, October 20, 2017 / Rules and Regulations 48771 

I. Background 

The Clinical Laboratory Improvement 

Amendments of 1988 (CLIA) (section 

353 of the Public Health Service Act, 

codified at 42 U.S.C. 263a) requires any 

facility performing examinations of 

human specimens (for example, tissue, 

blood, and urine) for diagnosis, 

prevention, or treatment purposes to be 

certified by the Secretary of the 

Department of Health and Human 

Services (HHS). The objective of the 

CLIA program is to ensure accurate and 

reliable laboratory testing. The Centers 

for Medicare & Medicaid Services (CMS) 

is responsible for the administration of 

CLIA. The Centers for Disease Control 

and Prevention (CDC) provides 

scientific and technical support/ 

consultation to HHS and CMS. The 

Food and Drug Administration (FDA) is 

responsible for test categorization. 

To receive a certificate of waiver 

(COW) under CLIA, a laboratory must 

only perform tests listed as waived in 

the CLIA regulations at 42 CFR 

493.15(c) (for example, urine pregnancy 

tests—visual color comparison tests) or 

tests which the FDA has determined to 

be waived because they are simple with 

an insignificant risk of error. Waived 

tests are exempt from most CLIA 

requirements, and the laboratories that 

perform them receive no routine 

surveys. 

Waived laboratories must meet only 

the following requirements under CLIA: 

• Enroll in the CLIA program; 

• Pay applicable certificate fees 

biennially; and 

• Follow manufacturers’ test 

instructions. 

Since the implementation of the CLIA 

program in 1992, the types of tests 

waived under CLIA have increased from 

8 to currently 97; consequently, the 

percentage of laboratories issued a COW 

has grown significantly from 20 percent 

to almost 72 percent of the approximate 

250,000 laboratories enrolled. 

Dipstick or tablet reagent urinalysis 

(non-automated) and fecal occult blood 

(FOB) are two of the original 8 waived 

tests published in the Federal Register 

in 1992, as specified at § 493.15(c)(1) 

and (2), respectively. The regulation 

specifies that waived test status is 

applicable to ‘‘non-automated’’ dipstick 

or tablet reagent urinalysis, but it does 

not specify ‘‘non-automated’’ for FOB 

tests. At the time the regulation was 

adopted, the FOB test was only 

available as a manual or non-automated 

test. However, there are now automated 

FOB analyzers that use complex and 

sophisticated technology, which do not 

meet the CLIA criteria for waiver and, 

therefore, should not be waived. It was 

therefore necessary to propose 

amendments to the regulations to 

exclude these automated tests from the 

list of waived tests in the CLIA 

regulations. 

Furthermore, since the development 

and proliferation of the waived test for 

hemoglobin by single analyte 

instruments with self-contained or 

component features, as described at 

§ 493.15(c)(9), it was our understanding 

that the non-automated hemoglobin by 

copper sulfate method at § 493.15(c)(6) 

was no longer in use. Therefore, we 

proposed to remove the hemoglobin by 

copper sulfate method from the list of 

waived tests at § 493.15(c)(6) if 

commenters confirmed that the method 

is no longer used. 

II. Provisions of the Proposed 

Regulations 

On November 7, 2014, we published 

a proposed rule in the Federal Register 

(79 FR 66348 through 66350) entitled, 

‘‘Clinical Laboratory Improvement 

Amendments (CLIA); Fecal Occult 

Blood (FOB) Testing.’’ In that rule, we 

proposed to revise § 493.15(c)(2) by 

adding the words ‘‘non-automated’’ 

following ‘‘Fecal occult blood.’’ This 

change would exclude the more 

complex automated FOB analyzers from 

the list of waived tests in the CLIA 

regulations. 

In addition, we proposed to remove 

the hemoglobin by copper sulfate 

method from the list of waived tests at 

§ 493.15(c)(6) if we received public 

comments confirming that this method 

is no longer used. 

Finally, we proposed to renumber the 

remaining paragraphs if § 493.15(c)(6) 

was removed. 

III. Analysis of and Responses to Public 

Comments 

In response to the November 7, 2014 

proposed rule, we received 7 public 

comments. Interested parties that 

submitted comments included blood 

donor centers, laboratories and 

accreditation organizations. A summary 

of the comments and our responses are 

as follows: 

Comment: One commenter supported 

our proposal to add the words ‘‘nonautomated’’ following ‘‘Fecal occult 

blood.’’ 

Response: We appreciate the 

commenters’ support. This change 

would exclude the more complex 

automated FOB analyzers from the list 

of waived tests in the CLIA regulations. 

Comment: In regard to our proposal to 

remove the hemoglobin by copper 

sulfate method from the list of waived 

tests if comments confirmed that this 

method is no longer used, one 

commenter stated that they collect 

approximately 10,000 units of blood per 

year and currently use the hemoglobin 

by copper sulfate method for cost 

reasons. Another commenter stated that 

they use the hemoglobin by copper 

sulfate method as a qualitative method 

to detect hemoglobin levels of 12.5g/dl 

or greater. 

Several commenters indicated that 

they use the hemoglobin by copper 

sulfate method to screen donors for 

acceptable pre-donation hemoglobin. 

Specifically, they perform 

approximately 20,000 to 30,000 tests per 

year. 

Response: In consideration of these 

public comments, which indicate that 

the hemoglobin by copper sulfate 

method is still in use, we are not 

finalizing our proposal to remove the 

hemoglobin by copper sulfate method 

from the list of waived tests at 

§ 493.15(c)(6). 

Comment: One commenter stated that 

it is appropriate to require ‘‘automated 

FOB tests’’ to be evaluated through the 

CLIA waiver process instead of 

automatically waiving these devices. 

However, the commenter believed that 

‘‘waived testing’’ poses risk to patients 

in certain settings and that any test that 

may result in harm should not be 

waived. 

Response: We appreciate the 

commenter’s support for requiring 

‘‘automated FOB tests’’ to be evaluated 

through the CLIA waiver process 

instead of automatically waiving these 

devices. According to section 263a(d)(3) 

of the CLIA statute, waived tests are 

simple laboratory examinations and 

procedures that have been approved by 

the FDA for home use or that, as 

determined by the Secretary, are simple 

laboratory examinations and procedures 

that have an insignificant risk of an 

erroneous result, including those that 

employ methodologies that are so 

simple and accurate that the likelihood 

of inaccurate result by the user is 

negligible, and those that the Secretary 

has determined pose no unreasonable 

risk of harm to the patient if performed 

incorrectly. Therefore, we believe that 

waived tests that are determined to have 

met the statutory criteria do not pose a 

significant risk of harm to patients. 

IV. Provisions of the Final Regulations 

We are adopting as final the provision 

set forth in the November 7, 2014 

proposed rule (79 FR 66348 through 

66350) with the following 

modifications: 

• In consideration of public 

comments, we are not finalizing our 

proposal to remove the hemoglobin by 


nlaroche on DSK9F9SC42PROD with RULES
48772 Federal Register / Vol. 82, No. 202 / Friday, October 20, 2017 / Rules and Regulations 

copper sulfate method from the list of 

waived tests at § 493.15(c)(6). 

• Since we are not removing 

§ 493.15(c)(6), we are not finalizing our 

proposal to renumber the remaining 

paragraphs in this section. 

V. Collection of Information 

Requirements 

This document does not impose 

information collection requirements, 

that is, reporting, recordkeeping or 

third-party disclosure requirements. 

Consequently, there is no need for 

review by the Office of Management and 

Budget under the authority of the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3501 et seq.). 

VI. Regulatory Impact Statement 

We have examined the impact of this 

rule as required by Executive Order 

12866 on Regulatory Planning and 

Review (September 30, 1993), Executive 

Order 13563 on Improving Regulation 

and Regulatory Review (January 18, 

2011), the Regulatory Flexibility Act 

(RFA) (September 19, 1980, Pub. L. 96– 

354), section 1102(b) of the Social 

Security Act, section 202 of the 

Unfunded Mandates Reform Act of 1995 

(March 22, 1995; Pub. L. 104–4), 

Executive Order 13132 on Federalism 

(August 4, 1999), the Congressional 

Review Act (5 U.S.C. 804(2)), and 

Executive Order 13771 on Reducing 

Regulation and Controlling Regulatory 

Costs (January 30, 2017). 

Executive Orders 12866 and 13563 

direct agencies to assess all costs and 

benefits of available regulatory 

alternatives and, if regulation is 

necessary, to select regulatory 

approaches that maximize net benefits 

(including potential economic, 

environmental, public health and safety 

effects, distributive impacts, and 

equity). A regulatory impact analysis 

must be prepared for major rules with 

economically significant effects ($100 

million or more in any 1 year). This rule 

does not reach the economic threshold 

and thus is not considered a major rule. 

This final rule amends the CLIA 

regulations at § 493.15(c)(2) to provide 

that only non-automated FOB tests are 

waived by the regulation. Automated 

test systems that detect FOB would, 

therefore, be subject to test 

categorization by the FDA as moderate 

or high complexity as described in 

§ 493.17. These test systems would only 

be considered for waiver approval if the 

manufacturer submits a waiver 

application to the FDA demonstrating 

the particular test system meets the 

statutory waiver criteria of being simple 

and having an insignificant risk of an 

erroneous result. 

As of July 11, 2017, the FDA CLIA test 

categorization database includes 134 

FOB test systems. Five of these test 

systems are automated and are 

categorized by the FDA as moderate 

(non-waived) complexity; all others are 

waived non-automated methods (http:// 

www.accessdata.fda.gov/scripts/cdrh/ 

cfdocs/cfCLIA/search.cfm). Only two of 

the five automated test systems are sold 

in the United States. Because the 

current regulation governing FOB tests 

does not specify automated or nonautomated FOB tests, it could be 

misconstrued that automated FOB test 

systems are available for use by 

laboratories with a COW. As amended, 

it will be clear that automated FOB test 

systems are not permitted for use by a 

laboratory with a COW under 

§ 493.15(c)(2). This means that testing 

sites using one or both of the two 

automated test systems noted above 

(which are categorized as moderate 

complexity tests) would be impacted by 

this rule if they are currently operating 

under a COW. According to the 

information on automated analyzers for 

FOB testing distributed in the United 

States provided by manufacturers, we 

estimate that no more than 26 

laboratories would be impacted by this 

regulatory change. We developed a 

range of the estimated economic impact 

for changes that may result from this 

final rule. Our highest estimate totals 

approximately $151,000 for the first 

year, due to the initial costs required to 

change certificate types for all 

potentially impacted laboratories. This 

would decrease in years two through 

five, projected to be as low as 

approximately $3,000 per year in years 

two and four, when no certificate fees 

would be paid. Therefore, this rule does 

not meet the economic threshold to be 

considered a major rule. 

The RFA requires agencies to analyze 

options for regulatory relief of small 

entities. For purposes of the RFA, small 

entities include small businesses, 

nonprofit organizations, and small 

governmental jurisdictions. Most 

hospitals and most other providers and 

suppliers are small entities, either by 

nonprofit status or by having revenues 

of less than $7.5 million to $38.5 

million in any 1 year. Individuals and 

states are not included in the definition 

of a small entity. We are not preparing 

an analysis for the RFA because we 

believe that approximately 79 percent of 

United States medical laboratories 

qualify as small entities based on their 

nonprofit status as reported in the 

American Hospital Association Fast 

Fact Sheet, updated July 11, 2017 

(http://www.aha.org/research/rc/statstudies/fast-facts.shtml). However, as 

previously described, due to the low 

number of automated analyzers 

distributed in the United States, we 

estimate that no more than 26 

laboratories would potentially be 

impacted by this regulatory change. As 

its measure of significant economic 

impact on a substantial number of small 

entities, HHS uses a change in revenue 

of more than 3 to 5 percent. We do not 

believe that this threshold would be 

reached by the requirements in this final 

rule because very few small entities 

would be subject to the provisions in 

this rule. 

In addition, section 1102(b) of the 

Social Security Act (the Act) requires us 

to prepare a regulatory impact analysis 

if a rule may have a significant impact 

on the operations of a substantial 

number of small rural hospitals. This 

analysis must conform to the provisions 

of section 604 of the RFA. For purposes 

of section 1102(b) of the Act, we define 

a small rural hospital as a hospital that 

is located outside of a Metropolitan 

Statistical Area for Medicare payment 

regulations and has fewer than 100 

beds. We do not expect this final rule 

to have a significant impact on a 

substantial number of small rural 

hospitals. The changes in this final rule 

would apply only to the laboratories 

previously described, which do not 

include any small rural hospitals at this 

time. Thus, an analysis under section 

1102(b) of the Act is not required for 

this rulemaking. 

Section 202 of the Unfunded 

Mandates Reform Act of 1995 also 

requires that agencies assess anticipated 

costs and benefits before issuing any 

rule whose mandates require spending 

in any 1 year of $100 million in 1995 

dollars, updated annually for inflation. 

In 2017, that threshold is approximately 

$148 million. This rule will have no 

consequential effect on state, local, or 

tribal governments or on the private 

sector. 

Executive Order 13132 establishes 

certain requirements that an agency 

must meet when it promulgates a 

proposed rule (and subsequent final 

rule) that imposes substantial direct 

requirement costs on state and local 

governments, preempts state law, or 

otherwise has Federalism implications. 

Since this regulation does not impose 

any costs on state or local governments, 

the requirements of Executive Order 

13132 are not applicable. 

Executive Order 13771, entitled 

‘‘Reducing Regulation and Controlling 

Regulatory Costs,’’ was issued on 

January 30, 2017 (82 FR 9339, February 

3, 2017). Section 2(a) of Executive Order 

13771 requires an agency, unless 


nlaroche on DSK9F9SC42PROD with RULES
Federal Register / Vol. 82, No. 202 / Friday, October 20, 2017 / Rules and Regulations 48773 

prohibited by law, to identify at least 

two existing regulations to be repealed 

when the agency publicly proposes for 

notice and comment, or otherwise 

promulgates, a new regulation. In 

furtherance of this requirement, section 

2(c) of Executive Order 13771 requires 

that the new incremental costs 

associated with new regulations shall, to 

the extent permitted by law, be offset by 

the elimination of existing costs 

associated with at least two prior 

regulations. OMB’s interim guidance, 

issued on April 5, 2017, https://

www.whitehouse.gov/the-press-office/ 

2017/04/05/memorandumimplementing-executive-order-13771- 

titled-reducing-regulation, explains that 

for Fiscal Year 2017 the above 

requirements only apply to each new 

‘‘significant regulatory action that 

imposes costs.’’ It has been determined 

that this final rule is not a ‘‘significant 

regulatory action thus does not trigger 

the above requirements of Executive 

Order 13771. 

List of Subjects in 42 CFR Part 493 

Administrative practice and 

procedure, Grant programs—health, 

Health facilities, Laboratories, Medicaid, 

Medicare, Penalties, Reporting and 

recordkeeping requirements. 

For the reasons set forth in the 

preamble, the Centers for Medicare & 

Medicaid Services amends 42 CFR part 

493 as set forth below: 

PART 493—LABORATORY 

REQUIREMENTS 

■ 1. The authority citation for part 493 

continues to read as follows: 

Authority: Sec. 353 of the Public Health 

Service Act, secs. 1102, 1861(e), the sentence 

following sections 1861(s)(11) through 

1861(s)(16) of the Social Security Act (42 

U.S.C. 263a, 1302, 1395x(e), the sentence 

following 1395x(s)(11) through 1395x(s)(16)), 

and the Pub. L. 112–202 amendments to 42 

U.S.C. 263a. 

■ 2. Section 493.15 is amended by 

revising paragraph (c)(2) to read as 

follows: 

§ 493.15 Laboratories performing waived 

tests. 

* * * * * 

(c) * * * 

(2) Fecal occult blood-non-automated; 

* * * * * 

Dated: August 24, 2017. 

Seema Verma, 

Administrator, Centers for Medicare & 

Medicaid Services. 

Dated: October 5, 2017. 

Anne Schuchat, 

RADM, U.S. Public Health Service, Principal 

Deputy Director, Centers for Disease Control 

and Prevention. 

Dated: October 12, 2017. 

Eric D. Hargan, 

Acting Secretary, Department of Health and 

Human Services. 

[FR Doc. 2017–22813 Filed 10–19–17; 8:45 am] 

BILLING CODE 4120–01–P 

FEDERAL COMMUNICATIONS 

COMMISSION 

47 CFR Parts 1 and 20 

[GN Docket No. 13–111; FCC 17–25] 

Promoting Technological Solutions to 

Combat Contraband Wireless Devices 

in Correctional Facilities 

AGENCY: Federal Communications 

Commission. 

ACTION: Final rule; announcement of 

effective date. 

SUMMARY: In this document, the Federal 

Communications Commission 

(Commission) announces that the Office 

of Management and Budget (OMB) has 

approved, for a period of three years, the 

information collection associated with 

the Commission’s Report and Order, 

FCC 17–25. This document is consistent 

with the Report and Order, which stated 

that the Commission would publish a 

document in the Federal Register 

announcing OMB approval of the 

information collection requirement and 

the relevant effective date of the rules. 

DATES: The rule amendments to 47 CFR 

1.9020(n), 1.9030(m), 1.9035(o), and 

20.23(a), published at 82 FR 22742, May 

18, 2017, which required OMB 

approval, are effective on October 20, 

2017. The rule amendments to (1) 47 

CFR 1.9020(d)(8), 1.9030(d)(8), 

1.9035(d)(4), and 20.18(a), which did 

not require OMB approval; and (2) 47 

CFR 20.18(r), which required OMB 

approval, published at 82 FR 22742, 

May 18, 2017, are effective on February 

12, 2018. 

FOR FURTHER INFORMATION CONTACT: For 

additional information, contact Cathy 

Williams by email at Cathy.Williams@

fcc.gov and telephone at (202) 418– 

2918. 

SUPPLEMENTARY INFORMATION: This 

document announces that, on October 2, 

2017, OMB approved the information 

collection requirement contained in the 

Commission’s Report and Order, FCC 

17–25, published at 82 FR 22742, May 

18, 2017. The OMB Control Number is 

3060–1243. The Commission publishes 

this document as an announcement of 

the effective dates of the rules. Note that 

the rules effective on February 12, 2018, 

as listed above, are effective on that date 

pursuant to the Report and Order, 

paragraph 142, the date 270 days after 

publication of the text or a summary 

thereof in the Federal Register. If you 

have any comments on the burden 

estimates listed below, or how the 

Commission can improve the collection 

and reduce any burdens caused thereby, 

please contact Cathy Williams, Federal 

Communications Commission, Room 1– 

C823, 445 12th Street SW., Washington, 

DC 20554. Please include the OMB 

Control Number 3060–1243 in your 

correspondence. The Commission will 

also accept your comments via email at 

PRA@fcc.gov. 

To request materials in accessible 

formats for people with disabilities 

(Braille, large print, electronic files, 

audio format), send an email to fcc504@

fcc.gov or call the Consumer and 

Governmental Affairs Bureau at (202) 

418–0530 (voice), (202) 418–0432 

(TTY). 

Synopsis 

As required by the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3507), 

the Commission is notifying the public 

that it received final OMB approval on 

October 2, 2017, for the information 

collection requirement contained in 47 

CFR 1.9020(n), 1.9030(m), 1.9035(o), 

20.18, and 20.23(a), as amended in the 

Commission’s Report and Order, FCC 

17–25. 

Under 5 CFR part 1320, an agency 

may not conduct or sponsor a collection 

of information unless it displays a 

current, valid OMB Control Number. No 

person shall be subject to any penalty 

for failing to comply with a collection 

of information subject to the Paperwork 

Reduction Act that does not display a 

current, valid OMB Control Number. 

The OMB Control Number is 3060– 

1243. 

The foregoing notice is required by 

the Paperwork Reduction Act of 1995, 

Public Law 104–13, October 1, 1995, 

and 44 U.S.C. 3507. The total annual 

reporting burdens and costs for the 

respondents are as follows: 

OMB Control Number: 3060–1243. 

OMB Approval Date: October 2, 2017. 

OMB Expiration Date: October 31, 

2020. 

Title: Sections 1.9020(n), 1.9030(m), 

1.9035(o), Community notification 

requirement for certain contraband 


nlaroche on DSK9F9SC42PROD with RULES